Hepatocyte-Targeted MR Contrast Agents: Contrast Enhanced Detection of Liver Cancer in Diffusely Damaged Liver

Tanimoto, Akihiro; Kuribayashi, Sachio

doi:10.2463/mrms.4.53

Cited by 10 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several reports that liver-specific MR contrast agent, such as super-paramagnetic iron oxide (SPIO), can increase detection sensitivity of hepatic tumors (13,14). SPIO particles act as a negative contrast agent and cause local magnetic field inhomogeneity, resulting in considerable T2 Ã shortening (15).…”

mentioning

confidence: 99%

Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats

et al. 2011

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Similarly, the asialoglycoprotein (ASG) receptor, a C-type lectin on healthy hepatocytes has been studied to detect cancerous lesions in the rat liver [68,69]. These receptors show a high affinity for galactoseterminated glycoproteins like arabinogalactan (AG).…”

Section: Normal Tissue Targeted Nanoparticlesmentioning

confidence: 99%

Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles

Islam

Josephson

2009

CBM

View full text Add to dashboard Cite

Superparamagnetic iron oxide nanoparticles (SPIO) are novel MRI contrast agents. After cellular uptake, SPIO cause a negative T2 contrast in MRI. Passive targeting strategies rely on SPIO uptake in reticuloendothelial cells by receptor-mediated phagocytosis. Active targeting employs SPIO-conjugates with specific targeting ligands which selectively bind to biomarkers on target cells. Several receptor systems are overexpressed in cancerous diseases and have been investigated as targets for ligand-directed SPIO. Targeting receptors undergo repeated recycling to the cell surface and internalization and bind further SPIO, thereby amplifying the magnetic signal. Malignant cell degeneration may also lead to loss of specific receptor activity. SPIO-conjugates directed at those receptors lead to a prominent reduction in signal intensity in healthy tissue but not the tumor. These strategies allow for molecular profiling of target cells and potentially enable the early detection of malignant diseases, more accurate staging, and treatment monitoring. With the advent of multimodality imaging techniques like targeted nanoparticle-enhanced MRI and near infrared optical fluorescence imaging, the combined advantages of different systems can be exploited.

show abstract

“…These NPs are biocompatible and are usually around 10–30 nm in diameter [ 20 , 21 , 22 ]. They have been widely used as FDA-approved contrast agents for magnetic resonance imaging (MRI) [ 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ]. They have also been used for determining pharmacokinetics, which is the distribution and release of drugs after their administration.…”

Section: Introductionmentioning

confidence: 99%

A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery

Leach

Wang

et al. 2016

IJMS

View full text Add to dashboard Cite

The side effects of radio- and chemo-therapy pose long-term challenges on a cancer patient’s health. It is, therefore, highly desirable to develop more effective therapies that can specifically target carcinoma cells without damaging normal and healthy cells. Tremendous efforts have been made in the past to develop targeted drug delivery systems for solid cancer treatment. In this study, a new aptamer, A10-3-J1, which recognizes the extracellular domain of the prostate specific membrane antigen (PSMA), was designed. A super paramagnetic iron oxide nanoparticle-aptamer-doxorubicin (SPIO-Apt-Dox) was fabricated and employed as a targeted drug delivery platform for cancer therapy. This DNA RNA hybridized aptamer antitumor agent was able to enhance the cytotoxicity of targeted cells while minimizing collateral damage to non-targeted cells. This SPIO-Apt-Dox nanoparticle has specificity to PSMA+ prostate cancer cells. Aptamer inhibited nonspecific uptake of membrane-permeable doxorubic to the non-target cells, leading to reduced untargeted cytotoxicity and endocytic uptake while enhancing targeted cytotoxicity and endocytic uptake. The experimental results indicate that the drug delivery platform can yield statistically significant effectiveness being more cytotoxic to the targeted cells as opposed to the non-targeted cells.

show abstract

Hepatocyte-Targeted MR Contrast Agents: Contrast Enhanced Detection of Liver Cancer in Diffusely Damaged Liver

Cited by 10 publications

References 33 publications

Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats

Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats

Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles

A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery

Contact Info

Product

Resources

About